0|10000|Public
30|$|This {{work was}} {{supported}} by funding from Takeda Pharmaceuticals. All aspects of the study design, interpretation, and <b>decision</b> <b>to</b> submit <b>for</b> <b>publication</b> were determined by the authors.|$|R
30|$|Funding {{for this}} study was {{provided}} by Eli Lilly and Company, Indianapolis, IN, USA. All aspects of the study design, interpretation, and <b>decision</b> <b>to</b> submit <b>for</b> <b>publication</b> were determined by the authors.|$|R
30|$|This {{work was}} {{supported}} by the project BetaImage, under grant agreement no. 222980. We declare that the funding did not influence the study design, data collection, analysis, interpretation, writing of the report and <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b>|$|R
30|$|No {{funding was}} {{involved}} in the preparation of this article or in the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b>|$|R
30|$|The {{sponsors}} of the study had no role in study design, data collection, data interpretation, or writing of the report. All authors had full {{access to all the}} data in the study, and the corresponding author had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b>|$|R
40|$|Funding: This {{study was}} {{exclusively}} funded from departmental sources. Only the contributing authors had {{any role in}} the design of the study, analysis of the data, preparation of the manuscript, or <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Competing Interests: The authors declare that no competing interests exist. Citation: Blum J, Kochs E, Forster N...|$|R
40|$|GR 071669 MA. The study sponsor had no role {{in study}} design, data collection, data analysis, data interpretation, or writing of the report. The {{corresponding}} author had full {{access to all the}} data in the study and had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Competing Interests: The authors have declared that no competin...|$|R
40|$|Rheumatology Research Foundation Medical Student Preceptorship Award (Lateef/Nelson), NIAMS K 23 AR 061406 (Nelson); NIH/NIAMS P 60 AR 064166 and U 01 DP 003206 (Jordan/Renner), NIH/NIAMS R 01 AR 067743 (Golightly). The funders had no role {{in study}} design; collection, analysis, or {{interpretation}} of data; writing the manuscript or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPublisher PD...|$|R
30|$|This {{study was}} {{supported}} by funding to LBW and JAB from the NIH (HL 103836, HL 117676) and funding support to LSM from Office of Medical Student Research and Vanderbilt University School of Medicine. The funding bodies had no role in study design, in collection, analysis, or interpretation of data, or in writing of the manuscript or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b>|$|R
40|$|Funding: The trial sponsor and funder, the Medical Research Council, {{provided}} {{peer review}} of the trial protocol and was represented on the trial Steering Committee, but had no other role in the study design, the collection, analysis or interpretation of data, writing of the paper, or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Competing Interests: The authors have declared that no competing interests exist...|$|R
40|$|Acknowledgements Funding: Chest, Heart and Stroke Scotland, grant ref. R 13 /A 148. The funder had no role {{in study}} design, data collection, {{analysis}} and interpretation, writing of the manuscript, and in the <b>decision</b> <b>to</b> submit the manuscript <b>for</b> <b>publication.</b> All authors had full {{access to all the}} data in the study. The corresponding author had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPostprintPostprin...|$|R
40|$|None of {{the authors}} {{received}} compensation for study design, study analysis, or manuscript preparation. The authors maintained full editorial control of the manuscript content and the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> 2 List of Abbreviations BMI = body mass index CHD = coronary heart disease HDL-C = high-density lipoprotein cholesterol HMG CoA = 3 -hydroxy 3 -methyglutaryl coenzyme A LDL-C = low-density lipoprotein cholestero...|$|R
40|$|This {{study was}} funded by Chest, Heart and Stroke Scotland (CHHS), Grant no. R 13 /A 148. The funder had no role in study design, data collection, {{analysis}} and interpretation, writing of the manuscript, and in the <b>decision</b> <b>to</b> submit the manuscript <b>for</b> <b>publication.</b> All authors had full {{access to all the}} data in the study. The corresponding author had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPostprin...|$|R
40|$|Pharma and AAA in a {{consultant}} role; other authors declared no conflict of interests. Funding: Supported {{in part by}} Novartis Oncology. The funder sponsored the purchase of SEER-Medicare data and provided funding for analytical support. All authors had unrestricted access to the final study data on request, were responsible for data interpretation, manuscript preparation, and the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication,</b> and attest <b>to</b> the completeness and accuracy of the data and statistical analysis...|$|R
30|$|The {{authors would}} like to thank the record {{officers}} at A & E department of the BVH for their help in data retrieval. No funding was received for this study or in the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b>|$|R
40|$|Products. These organisations {{were not}} {{involved}} in study design, the collection, analysis, or interpretation of data, or writing the manuscript, or <b>decisions</b> <b>to</b> submit <b>for</b> <b>publication.</b> Representatives of Tibotec-Virco were involved {{in the design of the}} trial and provision of resistance test results. They reviewed this manuscript but declined authorship on the basis of irreconcilable differences relating to trial methodology and conclusions. They were therefore not involved in the interpretation of data, writing the manuscript, nor the <b>decision</b> <b>to</b> publish...|$|R
40|$|Funding: {{this study}} was {{supported}} by Pharmacia Ltd., Erlangen, Germany and the Leukämie-Initiative Bonn e. V. The sponsors had no influence on the evaluation of data, the preparation of the manuscript or the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> Assistance with documentation was provided by Megapharm Ltd. ...|$|R
40|$|Acknowledgements This article {{presents}} independent research {{funded by the}} National Institute for Health Research (NIHR) under its Programme Grants for Applied Research Programme (Grant Reference Number RP-PG- 0707 - 10124). The views expressed {{in this article are}} those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. The funders had no role in study design, data collection, data analysis, data interpretation, writing of the report or <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPublisher PD...|$|R
40|$|Disclosure: BS is {{supported}} by a Vice Chancellors scholarship at the University of Greenwich, but this did not affect the research in any way or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> None of the other authors have any disclosures of conflicts of interest to declare. Background. Pain and recurrent falls are highly problematic in community-dwelling older adults, yet the association remains elusive. Objective. The objective {{of this study was to}} inves-tigate the association between pain and recurrent falls in community-dwelling older adults. Design. Two independent reviewers conducted searches of major electronic databases, complete...|$|R
40|$|Funding: This {{work was}} {{supported}} by a Chief Scientist Office postdoctoral training fellowship in health services research and health of the public research (ref PDF/ 12 / 06). The views expressed here {{are those of the authors}} and not necessarily those of the Chief Scientist Office. The funder did not have any role in the study design; the collection, analysis, and interpretation of data; the writing of the report; nor the <b>decision</b> <b>to</b> submit the paper <b>for</b> <b>publication.</b> DJM had full access to all the data in the study and had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPublisher PD...|$|R
30|$|The bipolar case–control genetic {{association}} {{study was}} funded by an unrestricted grant from GlaxoSmithKline Research and Development. Funding for the depression case–control study {{was provided by the}} UK Medical Research Council (MRC; G 0701420). The BADGE study was supported by an Interdisciplinary Ph.D. studentship from the UK Economic Social Research Council (ESRC) and MRC to Dr. Hosang. Prof. Uher is supported by the Canada Research Chairs program ([URL] and Dr. Fisher is supported by an MQ Fellows Award (MQ 14 F 40). The sources of funding had no involvement in the study design, data collection or <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b>|$|R
30|$|This {{work was}} {{supported}} by Genentech, Inc. Although Sponsor employees were involved at all stages of project development (the design of the study, the collection, analysis, and interpretation of data, and {{the writing of the}} manuscript), each of the authors independently arrived at and approved the final interpretation of the findings and each independently made the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b>|$|R
40|$|Support statement: This {{work was}} funded in its {{entirety}} by a project grant awarded by the Chief Scientist's Office of the Scottish Government Health Dept (CZG/ 2 / 573). The funding source had {{no role in the}} study design, data collection, analysis, and interpretation, in preparation of the manuscript, or the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> Peer reviewedPublisher PD...|$|R
30|$|We {{acknowledge}} the guidance provided by Dr. T.C. Agampodi and Professor Sisira Siribaddana. The authors sincerely thank to Dr. R.M.G.K. Rathnayake for her contribution during literature search. We also appreciate the help provided by Dr. Kosala Weerakoon during retrieving of articles. This study was partially funded by Rajarata University Research Grant 2013 (Grant Nos.: RJT/RP and HDC/ 2013 /Med. and Alli.Sci./R/ 02). The funding body {{did not have}} any role in the design, collection, analysis, or interpretation of the study, nor did it have any role in the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> We {{would like to thank the}} anonymous reviewers for their valuable comments and suggestions to improve this manuscript.|$|R
40|$|There are no {{conflicts}} of interest pertaining to {{the writing of the}} manuscript and submission <b>for</b> <b>publication</b> There are no funding sources involved in the writing of the manuscript or the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> None of the authors have been paid to write this manuscript by a pharmaceutical company or other agency. The corresponding author certifies that she had full access to all the data in preparation of the manuscript and has final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Manuscript preparation and the <b>decision</b> <b>to</b> submit <b>for</b> was carried out in accordance with universal ethical principles Eighty percent of the population in the developing world relies on traditional medicine, and 70 - 80 % of the population in developed countries utilizes complementary therapies. Though a vibrant healing tradition pervades modern life in the Arab and Muslim world, no clear definition or model exists to organize it’s multiple and intertwined elements. We define Traditional Arabic and Islamic Medicine (TAIM) as a system of healing practiced since antiquity in the Arab world within the context of religious influences of Islam and comprised of medicinal herbs, dietary practices, mind-body therapy, spiritual healing and applied therapy whereby many of these elements reflect an enduring interconnectivity between Islamic medical and prophetic influences as well as regional healing practices emerging from specific geographical and cultural origins. Our definition an...|$|R
40|$|None of the funders had {{any role}} in the study design nor in the collection, analysis, or {{interpretation}} of data. The funders did not contribute to writing of the paper nor <b>to</b> the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> Competing Interests: The authors have declared that no competing interests exist. Citation: Hallett RL, Dunyo S, Ord R, Jawara M, Pinder M, et al. (2006...|$|R
40|$|Funding: The {{study was}} {{sponsored}} by Outside In. Outside In had no involvement in the study design; collection, analysis, and interpretation of data; writing of the paper; and <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> KVD is the guarantor and as such is responsible for interpreting and presenting the data. Competing Interests: The authors have declared that no competing interests exist. Citation: Danilenko KV, Samoilov...|$|R
40|$|We thank Jackie Caldwell, Iain Bishop, Grant Wyper, Kjersti Fergusson, and Martyn Ritchie in NHS National Services Scotland Information Services Division and {{all members}} of the Advisory Group for their contribution. Funding: The study was funded by Scottish Government Chief Scientist Office project grant CZH/ 3 / 17. The funder of the study had no role in study design, data collection, data analysis, data interpretation, or the writing of the report. The {{corresponding}} author had full access to all the data in the study and had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> ST works at the Health Services Research Unit, University of Aberdeen, which is funded by the Chief Scientist Office of the Scottish Government Health Directorates. Peer reviewedPublisher PD...|$|R
40|$|Funding: FMKW is {{supported}} by Arthritis Research UK grant 20682 and by EU FP 7 project Pain-omics. AB reports an Ambizione personal career fellowship by the Swiss National Science Foundation and a project grant from the Swisslife Jubiläumsstiftung. Generation Scotland (www. generationscotland. org) has received core funding from the Chief Scientist Office of the Scottish Government Health Directorates CZD/ 16 / 6 and the Scottish Funding Council HR 03006. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report, or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> The corresponding author had full {{access to all the}} data in the study and had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> TwinsUK (www. twinsuk. ac. uk) : the study was funded by the Wellcome Trust; European Community’s Seventh Framework Programme (FP 7 / 2007 - 2013). The study also receives support from the National Institute for Health Research (NIHR) - funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. The funders had no role in study design, data collection and analysis, <b>decision</b> <b>to</b> publish, or preparation of the manuscript. Acknowledgments We are grateful to the families who took part in GS:SFHS, the GPs and Scottish School of Primary Care for their help in recruiting them, and the whole Generation Scotland team, which includes academic researchers, clinic staff, laboratory technicians, clerical workers, statisticians and research managers. FMKW {{is supported}} by Arthritis Research UK grant 20682 and by EU FP 7 project Painomics. AB reports an Ambizione personal career fellowship by the Swiss National Science Foundation and a project grant from the Swisslife Jubilaumsstiftung. [URL] reviewedPublisher PD...|$|R
30|$|Fresenius Kabi {{supported}} {{data collection}} with an unrestricted grant. The sponsor did not influence the study {{design and the}} data collection, analysis, interpretation and writing of the manuscript and the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> The researchers are independent from the sponsor and all authors had full access {{to all of the}} data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.|$|R
40|$|Author’s contributions: RAC {{participated in}} planning, obtaining results, {{analysis}} and interpretation of data, drafting the manuscript and in the <b>decision</b> <b>to</b> submit it <b>for</b> publication; LAR participated in the planning, {{analysis and interpretation}} of data, drafting the manuscript and in the <b>decision</b> <b>to</b> submit it <b>for</b> publication; CMS participated in the planning, analysis and interpretation of data, drafting the manuscript and in the <b>decision</b> <b>to</b> submit it <b>for</b> publication; JABM participated in the planning, analysis and interpretation of data, drafting the manuscript and in the <b>decision</b> <b>to</b> submit it <b>for</b> publication; ROD, principal investigator, participated in planning, obtaining results, analysis and interpretation of data, drafting the manuscript and in the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication...</b>|$|R
40|$|SA 3569 and S 1932 – 21 / 21), and the Department for International Development (DFID) {{provided}} {{financial support}} for this study. The funders had no involvement in study design, data collection, data analysis, data interpretation, {{in the writing of}} the paper, or in the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> Objectives: <b>To</b> compare the efficacy and safety of artemisinin combination therapies for the treatment of uncomplicated falciparum malaria in Uganda. Design: Randomized single-blind controlled trial. Setting: Tororo, Uganda, an area of high-level malaria transmission. Participants: Children aged one to ten years with confirmed uncomplicated P. falciparum malaria. Interventions: Amodiaquine þ artesunate or artemether–lumefantrine...|$|R
40|$|Institutes of Health, and the NTDModelling Consortium by the Bill and Melinda Gates Foun-dation in {{partnership}} with the Task Force for Global Health. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the article. The corre-sponding author had full access to all the data in the study and had final responsibility <b>for</b> the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> There is an omission in the Acknowledgments section. Please see the update Acknowledg-ments section here: In addition to the PRET, MIDAS and NTDModelling Consortium study sponsors, the authors thank the data and safety monitoring committee, including Douglas Jabs, MD, MBA (chair), Antoinette Darville, MD, Maureen Maguire, PhD, and Grace Saguti, MD, who were generous with their time and advice and met before and during the study. The authors thank all of our colleagues in Niger at Programme National de Santé Oculaire who col-lected samples and data. We also thank the NTD support center, the Task Force for Global Health, and the 15 experts surveyed at the WHONTD-STAGMonitoring and Evaluatio...|$|R
40|$|Funding: Support {{for this}} study was {{provided}} by the Bill and Melinda Gates Foundation to Family Health International (FHI). The views expressed in this article do not necessarily reflect those of FHI or the Bill and Melinda Gates Foundation. Gilead Sciences provided the tenofovir disoproxil fumarate and placebo pills used in the study. Analysis of drug resistance was supported by National Institutes of Health grant RO 1 AI 062333. RR is with the Bill and Melinda Gates Foundation and HJ is with Gilead Sciences; both contributed to study design, as well as writing/reviewing the paper and the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> LP has access to all the data and has responsibility for the accuracy of the manuscript. Competing Interests: HSJ is an employee and shareholder of Gilead Sciences, which provided tenofovir disoproxil fumarate and matching placebo for the study. RR is with the Bil...|$|R
40|$|Acknowledgments We {{thank the}} members of the Trial Steering and Data Monitoring Committee and all the people who helped in the conduct of the study (including the OPPTIMUM {{collaborative}} group and other clinicians listed in the appendix). We are grateful to Paul Piette (Besins Healthcare Corporate, Brussels, Belgium) and Besins Healthcare for their kind donation of active and placebo drug for use in the study, and to staff of the pharmacy and research and development departments of the participating hospitals. We are also grateful to the many people who helped in this study but who we have been unable to name, and in particular all the women (and their babies) who participated in OPPTIMUM. OPPTIMUM was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a Medical Research Council (MRC) and National Institute of Health Research (NIHR) partnership, award number G 0700452, revised to 09 / 800 / 27. The EME Programme is funded by the MRC and NIHR, with contributions from the Chief Scientist Office in Scotland and National Institute for Social Care and Research in Wales. The views expressed in this publication are those of the author(s) and not necessarily those of the MRC, National Health Service, NIHR, or the Department of Health. The funder had no involvement in data collection, analysis or interpretation, and no role in the writing of this manuscript or the <b>decision</b> <b>to</b> submit <b>for</b> <b>publication.</b> Peer reviewedPublisher PD...|$|R
40|$|None of the funders had {{any role}} in the study design nor in the collection, analysis, or {{interpretation}} of data. The funders did not contribute to writing of the paper nor <b>to</b> the <b>decision</b> <b>to</b> submit it <b>for</b> <b>publication.</b> PLoS CLINICAL TRIALS Objectives: In the Gambia, the combination of chloroquine (CQ) and sulphadoxinepyrimethamine (SP) has replaced CQ monotherapy for treatment of malaria caused by Plasmodium falciparum. We measured {{the efficacy of the}} combination CQ/SP, and the prevalence of parasites carrying alleles associated with resistance to CQ or SP. Design: We conducted a single-blind, randomised, controlled trial to compare the efficacy of CQ/SP to that of SP or CQ alone. Setting: The study took place in the town of Farafenni and surrounding villages in the Gambia. Competing Interests: The authors have declared that no competing interests exist. Citation: Dunyo S, Ord R, Hallett R, Jawara M, Walraven G, et al. (2006) Randomised trial of chloroquine/ sulphadoxine-pyrimethamine in Gambian children with malaria: Impact against multidrug-resistant P. falciparum. PLoS Clin Trials 1 (3) : e 14...|$|R
